Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2

Conditions

Uveal Melanoma 2Conjunctival Neoplasms 1

Interventions

Cyclophosphamide 910Carboplatin 787pembrolizumab 746Paclitaxel 744Bevacizumab 716Cisplatin 708Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 338Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Ranibizumab × Clear all
NCT00456495 2017-07-21

Effect of Ranibizumab on Malignant Conjunctival Neoplasia

The New York Eye Cancer Center

Phase 1 Completed
5 enrolled 6 charts

Conjunctival Neoplasms

NCT00680225 2017-04-12

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

New England Retina Associates

Phase 3 Completed
10 enrolled 4 charts
Dermatologic

Uveal Melanoma

NCT01251978 2016-10-19

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

New England Retina Associates

Phase 2 Completed
10 enrolled 7 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡